Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tivantinib Maintenance in Extended SCLC
NCT02608411Phase 2Terminated
- Sponsor
- Istituto Oncologico Veneto
- Start
- Feb 2016
- Primary completion
- Feb 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of tivantinib in small cell lung cancer (SCLC), sponsored by Istituto Oncologico Veneto. Started Feb 2016; status: terminated.
02
Drugs
tivantinib
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT02608411.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02608411.